Halozyme Therapeutics, Inc. - HALO STOCK NEWS

Halozyme Therapeutics announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment for testosterone replacement therapy, on June 7, 2022. TLANDO was approved by the FDA on March 28, 2022. This launch follows the introduction of XYOSTED in 2018, marking Halozyme's second product in this category. Executives emphasized that TLANDO provides a convenient dosing option requiring no titration, targeting the growing market of male hypogonadism, estimated to affect 30-50% of men with obesity or type 2 diabetes.

Halozyme Therapeutics has successfully completed its acquisition of Antares Pharma, finalizing the payment for shares tendered at $5.60 each. This strategic acquisition aims to enhance Halozyme's capabilities in biopharmaceutical development, particularly through its proprietary ENHANZE® technology, which aims to improve patient treatment experiences. Antares, now a wholly-owned subsidiary, will cease trading on NASDAQ following this merger. Financial advisors included BofA Securities and Wells Fargo, confirming the significant market interest in this consolidation.

Halozyme Therapeutics announced the expiration of the waiting period under the HSR Act for its acquisition of Antares Pharma. The tender offer commenced on April 26, 2022, at a price of $5.60 per share. The offer's completion is contingent upon the tendering of a majority of Antares shares and other customary conditions. The offer is set to expire on May 23, 2022, unless extended. This acquisition aims to enhance Halozyme's innovative therapy offerings, leveraging Antares' expertise in drug delivery systems.

Halozyme Therapeutics reported a strong first quarter of 2022, with revenue of $117.3 million, marking a 32% year-over-year increase. GAAP diluted earnings per share rose to $0.43 while non-GAAP diluted EPS reached $0.47. Record quarterly royalties hit $69.6 million, an 89% growth compared to the prior year. The company reiterated its full-year 2022 revenue guidance of $530 million to $560 million, forecasting 20-26% growth and a GAAP operating income of $350 million to $380 million.

Halozyme Therapeutics (NASDAQ: HALO) announces a Q1 2022 Conference Call on May 10 at 4:30 p.m. ET. Dr. Helen Torley will lead the discussion. Financial results for the quarter ending March 31, 2022 will be released following market close on the same date. Interested parties can register for the call via the provided link and access the live webcast through the Investors section of Halozyme's website. The company highlights its innovative ENHANZE® technology, which improves drug delivery, benefiting over 600,000 patients globally.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) has initiated a cash tender offer to acquire all outstanding common shares of Antares Pharma, Inc. (NASDAQ: ATRS) for $5.60 per share. The offer follows the Merger Agreement dated April 12, 2022, and is set to expire on May 23, 2022, unless extended. Conditions for closing include the tender of a majority of Antares shares and compliance with regulatory approvals. Antares' Board of Directors recommends stockholders accept the offer. The transaction aims to enhance Halozyme's position in the biopharmaceutical market.

Halozyme Therapeutics is set to acquire Antares Pharma for $5.60 per share, valuing the transaction at approximately $960 million. This acquisition aims to enhance Halozyme's drug delivery business and diversify its revenue streams through Antares' auto injector platform. The deal is anticipated to be immediately accretive to Halozyme's revenue and non-GAAP earnings in 2022, with significant growth projections into 2027. The merger is backed by both companies' boards and expected to close in the first half of 2022.

Halozyme Therapeutics (NASDAQ: HALO) announced a global collaboration with Chugai Pharmaceutical for the use of its ENHANZE^® drug delivery technology. Chugai will pay an upfront fee of $25 million and potential future payments totaling up to $160 million based on specific milestones. This agreement marks Halozyme's twelfth collaboration involving over 60 therapeutic targets and aims to enhance patient treatment options through subcutaneous injections. Halozyme will also benefit from royalties on sales of products utilizing this technology.

The recent Phase 3 ADAPT-SC study results demonstrate that subcutaneously administered efgartigimod shows noninferior total IgG reduction at day 29 compared to intravenous administration, a significant milestone for Halozyme (NASDAQ: HALO). This achievement positions the treatment for generalized myasthenia gravis (gMG) favorably, paving the way for argenx to submit a Biologics License Application (BLA) to the FDA by the end of 2022. The success underscores the effectiveness of Halozyme's ENHANZE® technology in enhancing drug delivery options.